DJO Incorporated, Q4 2007 (F4Q07) (Qtr End 12/31/07) Earnings Call Transcript

DJO Incorporated (DJO)

Q4 2007 Earnings Call

March 24, 2008 1:00 pm ET

Executives

Mark Francois – Director, Investor Relations

Vicki Capps – Exec. VP & CFO

Analysts

Unspecified Analyst - Deutsche Bank

David Yu – Liberty Harbor

David Martin – BlueMountain Capital

Unspecified Analyst

[Ali Radinsky] – BridgeGate Capital Management

Presentation

Operator

Ladies and gentlemen thank you for standing by, I’m Mark Francois, Director of Corporate Communications and Investor Relations for DJO Incorporated. Thanks for joining us today for DJO’s conference call to discuss our fourth quarter and fiscal year end 2007 results. Speaking today will be Vicki Capps, Executive Vice President and Chief Financial Officer. During our prepared remarks you’ll be in a listen only mode. After our prepared remarks have been concluded we’ll open the call up for your questions. The conference call is being recorded today, March 24, 2008.

Before I turn it over to Vicki, I wanted to remind you that today’s conference call will contain forward-looking statements made under the Safe Harbor Provision of the Private Securities Litigation Reform Act of 1995. Such statements relate to the company’s operational and integration activities related to the merger of ReAble Therapeutics with DJO Incorporated; our cost reduction initiatives; sales and marketing strategies; future revenue and adjusted EBITDA projections and future cash flow expectations. These forward-looking statements are based on the company’s current expectations and are subject to a number of risks and uncertainties and assumptions that could cause actual results to differ materially from the forward-looking statements. The company undertakes no obligation to update any forward-looking statements whether as a result of new information, future events or otherwise. Many of these risks, uncertainties and assumptions are discussed in recent SEC filings for DJO Finance LLC, formally ReAble Therapeutics Finance LLC, including our current report on Form 8-K, filed on October 31, 2007 and our Form S4A, filed on May 1, 2007 both with the Securities and Exchange Commission.

These documents are readily available at www.reableinc.com. And with that I’ll hand the call over to Vicki.

Vicki Capps

Thank you Mark. Hello everyone and thank you for joining us today for our first conference call of the new DJO Incorporated. As a quick reminder for those of you who missed us on our road show last fall, the company I’m going to talk to you about today was formed from the merger of two orthopedic rehabilitation companies; ReAble Therapeutics Inc. and the former DJO Incorporated. The merger closed November 20, 2007.

ReAble has been a Blackstone portfolio company since November of 2006. DJO Incorporated was a public company traded on the New York Stock Exchange under the symbol DJO. DJO was acquired from its public shareholders in the merger for approximately $1.3 billion and became a wholly owned subsidiary of ReAble. At the same time we changed the name of ReAble to DJO Incorporated. Blackstone provided additional equity capital for the merger and we entered into a new senior secured credit facility which provided a $1.1 billion term loan, all of which was drawn at closing in an unused $100 million revolving line of credit.

We also sold $575 million of new 10 7/8% senior unsecured notes. In addition to providing the funds for the merger, these financings replaced existing credit facilities that existed at both DJO and ReAble. ReAble’s 11 ¾% senior subordinated notes also remain outstanding with the principal amount of $200 million.

We believe the combination of ReAble and DJO created the largest orthopedic rehabilitation company in the world with pro forma net sales of over $900 million and strong EBITA and cash flow. On a pro forma basis as if the merger and a few smaller acquisitions had all closed on January 1, 2006, our 2007 net sales would have been $929.5 million reflecting a 6.1% increase over pro forma net sales for 2006. And for the fourth quarter our pro forma growth rate accelerated to 11.7%. Our pro forma adjusted EBITDA for 2007 was $250.8 million or 27% of net sales.

This level of EBITDA nicely supports our new capital structure which consists of total equity investments of $823 million reflecting about 31% of our total capitalization and total net debt of approximately $1.8 billion. Our total net debt is just over 7x our adjusted EBITDA and our senior secured debt to adjusted EBITDA is about 4x.

The rationale for the ReAble DJO merger was compelling and pretty straight forward. The separate companies were very complimentary with DJO having focused primarily on the orthopedics’ market and ReAble focusing primarily on the physical therapy and rehab markets. On a combined basis, the new DJO holds leading market share across most of our addressable market segments with over 60% of net sales driven by products where we hold a number one market position. The scale of our international business is also quite significant and while growing well for both companies prior to the merger; on a combined basis our international opportunities should be a significant growth driver for us and should enable us to continue to expand our direct selling strategy in key markets.

The merger also permits us to accelerate new product development by cross-divisionally leveraging our various technology platforms and core competencies to generate future new products and product enhancements. Each separate company’s products are also underpenetrated in the core distribution channels of the other company. This gives us confidence that there should be substantial cross-selling opportunities in the new combined company.

And last but not least we have identified over $50 million of cost reduction opportunities available through integrating the businesses. With the merger now complete, we have a lot going on at the company and we are very optimistic about our future prospects. We are managing the new company through three business segments. These segments are domestic rehabilitation, international rehabilitation and surgical implant, which represent approximately 72%, 21% and 7% respectively of our total pro forma sales.

Our domestic rehabilitation segments includes the rigid knee braces, orthopedic soft goods, cold therapy and vascular systems products that were sold in the US by the legacy DJO under our market leading DonJoy, ProCare and Aircast brands. Also from the ReAble side of the business this segment includes the strong platforms in physical therapy and pain management provided by our Empi division with its ten, tens and muscle stimulation electrotherapy products, iontophersis transdermal drug delivery systems and home traction devices. We have also combined the legacy DJO regeneration segment which is our bone growth simulation business into the Empi division to take advantage of Empi’s center of excellence for insurance reimbursement.

Our Chattanooga division rounds out our domestic rehabilitation segment with physical therapy product lines that serve the clinical rehabilitation market including clinical electrotherapy devices in a variety of modalities, clinical traction devices, physical therapy products such as continuous passive motion machines and state-of-the-art treatment tables. Chattanooga’s products are considered the Gold Standard in the clinical physical therapy market.

Our domestic rehabilitation segment had pro forma revenue of $663.9 million for 2007 reflecting pro forma growth of 3.1% over 2006. For the fourth quarter of 2007 pro forma revenue for this segment was $165.6 million reflecting an accelerating growth rate of 7.6% over the fourth quarter of 2006.

Our international rehabilitation segment includes the international sales of our DonJoy, ProCare and Aircast products as well as our Ormed business which supplies bracing, CPM machines, electrotherapy and other products primarily in the German market and our Cefar-Compex business which primarily provides electrotherapy devices for both medical and consumer markets in Europe.

Our international rehab segment has pro forma revenue of $199 million for 2007 and enjoyed pro forma growth of 15.2% over 2006. For the fourth quarter of 2007 pro forma international revenue was $55.3 million reflecting growth of 19.2% over the fourth quarter of 2006.

Our third business segment is our surgical implants segment which we’ve renamed DJO Surgical. This business was formerly known as Encore Medical. This segment provides a wide variety of reconstructive hip, knee and shoulder implant products that serve the orthopedic reconstruction markets.

Our surgical implant segment had revenue of $66.6 million for 2007 which growth of 12.7% over 2006. For the fourth quarter of 2007 surgical implant revenue was $17.5 million reflecting growth of 33% over the fourth quarter of 2006.

It is still early days post closing but we are making very good progress and gaining traction on both our cost reduction initiatives as well as a growing list of revenue synergy opportunities. Let me first talk for a moment about the revenue synergies. Because ReAble and DJO share complimentary product lines in different segments of the orthopedic rehabilitation, pain management and physical therapy markets, and because the two businesses have complimentary but different distribution channels, we believe there are substantial cross-selling opportunities and we are aggressively pursing them and beginning to realize the benefits of doing so.

At the beginning of this year, we hosted a series of about 15 sales synergy meetings across the United States which were designed to accomplish three things. First to bring together all of our sales teams within a geographic area to establish relationships and share information about key customers of each sales team. Second to provide a high level overview of the combined product line of the new company and basic training on the key products. And third to introduce our new cross-referral program and explain how the sales reps will be paid for these cross-selling activities. Out of these meetings came targeted sales action plans for the largest regions of the United States.

These meetings and our subsequent activities have confirmed our views that the combination of the products and the sales channels of the separate companies will allow us to strengthen our franchises in both orthopedics and physical therapy and accelerate our growth rates by providing a broader range of products to a broader group of customers. Its obviously still early days but the cross-selling opportunities identified by our sales teams suggest that the contribution from revenue synergies could be significant.

The cross-selling opportunities that have begun to emerge include the opportunity to sell our DonJoy osteoarthritis knee braces through the Empi sales channel. The Empi sales force calls on physical therapists and pain specialists who often treat patients suffering from the affects of osteoarthritis long before those patients see an orthopedic surgeon who is the typical customer of our DonJoy sales force who is selling that product today.

On the other hand, the Empi sales force has historically carried a range of flexion contracture braces which are very well suited to be sold by the DonJoy channel that focuses on orthopedic surgeons who often treat patients who suffer from post-surgical or post-injury contracture issues.

Another exciting cross-selling opportunity comes from adding the products of the legacy DJO DonJoy, ProCare and Aircast franchises to opportunities presented by our surgical business. Following the merger we now have an opportunity to help manage the surgery patient with end-to-end solutions including surgical implants as well as post-operative pain management with either our electrotherapy devices or our cold therapy products, deep vein thrombosis prophylactics to prevent post-surgical blood clots and orthopedic bracing and soft goods for rehabilitation and physical therapy products to improve the outcome of long term recovery.

We believe our ability to offer this total patient solution will enable us to strengthen our relationships with surgeons and other orthopedic and healthcare professionals. These are just a few of the opportunities we are focused on. We continue to add others to a growing list of initiatives. To ensure we take full advantage of these opportunities we have appointed one of our Vice Presidents to a special new role focused on driving these identified revenue synergies.

Equally important to the merger thesis are the cost reduction opportunities presented by combining the companies. We expect to achieve over $50 million of near term cost savings opportunities and we believe we will ultimately achieve a significantly larger amount. We had an extensive integration plan well developed prior to closing the merger and since closing we have been hard at work executing on initiatives to reduce our cost of goods sold and eliminate duplicate general and administrative spending.

Some of these initiatives address the opportunity to consolidate certain business activities across our organization to take advantage of existing centers of excellence that define best practices and efficiencies for certain functions such as insurance reimbursement operations and manufacturing. We are also nearly finished integrating the former DJO Germany business into the ReAble Ormed business in Germany creating a much larger cost efficient German organization.

We have several opportunities to reduce cost of goods sold. Some of these include relocating certain manufacturing functions from the United States to our low cost award winning factory in Mexico, such as labor intensive cutting and sewing operations. We will also be replacing certain products sourced by ReAble from other manufacturers with comparable products manufactured by DJO. We’ve also added a Senior Vice President of Procurement to our organization that is busy renegotiating new procurement contracts with our vendors to yield savings on common raw materials, components and freight where our volumes have increased as a combined company.

And we are implementing the lean manufacturing principles employed by the legacy DJO throughout the ReAble manufacturing operations. We are also already achieving significant G&A savings through the elimination of duplicate corporate overhead and reducing our combined spending for insurance, programs, audit fees and other indirect items. We continue to view this integration as relatively low risk based on the fact that we are changing very little about how we interface with our customers and based on the fact that our combined management team has significant experience in successfully integrating and restructuring businesses.

We will be highly focused on cost reduction integration projects for at least the remainder of this year. During this time we will also be driving our culture of continuous improvement throughout the new combined company organization. This culture has proven to be very successful on the legacy DJO at helping us drive continued expansion of our top line growth rates and our profit margins. We expect the same for the new DJO.

Turning quickly to the financials, there is quite a bit of detail in today’s press release. As required most of the financial information in the release and in the Form 10-K we will file later this week is presented on a GAAP basis. Because of the significance of the merger and because ReAble and DJO have completed several other recent acquisitions the actual GAAP results are not reflective of the current ongoing operations of the new combined company. Accordingly I’d like to set the stage by explaining where we are today on a pro forma adjusted basis and how we expect 2008 to unfold.

I’ve already mentioned that including the merger and all other recent acquisitions on a pro forma basis for the full 2007 year total revenue was $929.5 million. Within the actual P&L results were significantly impacted by purchase accounting adjustments and other non-cash and non-recurring adjustments related to the merger and the other recent acquisitions. As permitted by our senior secured credit agreement, we have excluded the impact of these items from our presentation of adjusted EBITDA. Adjusted EBITDA also includes on a pro forma basis the full year EBIDTA from the legacy DJO and the other acquired businesses.

The senior secured credit agreement further permits us to include the estimated cost savings expected to be achieved from the DJO merger and the other acquisitions. After all these adjustments pro forma adjusted EBITDA was $250.8 million for 2007 or 27% of pro forma net revenue. Excluding the future cost savings which amount to $50.6 million for the DJO merger and approximately $16 million for the other acquisitions, pro forma operating EBITDA was $184.1 million for 2007 or 19.8% of pro forma net revenue.

Pro forma adjusted gross margin for 2007 also before future cost savings was 61.3% of pro forma net sales. Our consolidated accounts receivable were $154.8 million at 12/31/07 reflecting day’s sales outstanding of approximately 61 days and inventory levels were $110.9 million excluding the temporary impact of write-ups to fair value required by purchase accounting. And this reflects days in inventory of approximately 112 which translated into inventory turns of 3.2x.

On a combined basis capital expenditures were $20.1 million for 2007 or just 2.2% of pro forma net revenues. Our businesses did not really require much in the way of capital spending investment and an annual expenditure of 2% to 3% of revenue should generally be sufficient.

On a pro forma basis our pro forma adjusted EBITDA would have exceeded cash required to pay the pro forma interest on our debt as well as provide cash for a modest investment in working capital, our capital expenditures and a small amount of cash taxes and we would have generated excess cash flow of over $35 million on a pro forma basis for 2007.

These are the baseline financial metrics we expect to improve on in 2008. As we move through the year and execute on our business strategies as well as our synergy opportunities we expect 2008 revenue to approach $1 billion and we expect adjusted EBITDA margins to approach 30%. From a liquidity perspective we feel we are in very good shape and expect to generate positive cash flow well in excess of the pro forma cash flow for 2007. This increased cash will be generated by improving profitability as well as through initiatives focused on shaving a few days off both our accounts receivable balances and our inventory balances. We do have $100 million available on a revolving line of credit to help manage fluctuations in our cash flow but with cash balances exceeding $60 million at year-end; it is unlikely that we’ll be required to use the line.

We feel very comfortable with our 2008 plan and look forward to demonstrating the revenue growth and earnings potential of our new company as we move through 2008. With all that said, I hope today’s discussion has given you a flavor for what the new DJO is all about and the level of excitement we have about the opportunities in front of us. We will look forward to another opportunity to update you in just about six short weeks with our first quarter earnings announcement. We are also speaking tomorrow at the Credit Suisse Leveraged Finance conference in Phoenix and look forward to seeing some of you there.

With that said, I think we’re ready to open up the call for questions.

Question-and-Answer Session

Operator

Your first question comes from Unspecified Analyst - Deutsche Bank

Unspecified Analyst - Deutsche Bank

First, just on the integration, I know in the Mexico plant I think was fairly important to you and then also any impact of FX on the overall sales level for this year. I think it was considerably better than…the revenues were up considerably from the pro forma level in the red, but the EBIDTA was basically flat and I was just wondering why profitability didn’t include…kind of in time with the revenue that we saw from the pro forma in the red.

Vicki Capps

[inaudible] definitely did help us a bit at the top line and frankly to a certain extent of the EBITDA line in the fourth quarter and although that’s not fully baked into our projections for 2008 it certainly could give us a good tailwind as we move through this year as well assuming nothing changes. The fourth quarter I think it’s a bit hard to conclude on the actual financial results for the fourth quarter because the companies were separate. We closed the merger on November 20 and it’s hard to say that the merger itself didn’t have somewhat of an impact on the businesses. So we’ve done our best to pick out the expenses that directly related to the merger and were non-recurring or non-cash in nature and exclude those as we’re permitted to do. But the basis operations were not quite in line with our expectations. We believed primarily due to the distraction impact around the closing date of the merger. But we feel that that’s behind us and we certainly expect to see the earnings grow at a pace that would exceed the top line growth as we move forward.

Unspecified Analyst - Deutsche Bank

Would that be with the margin improvement, should that be in a step light fashion across the quarters or how do you think we should think about that in the coming year?

Vicki Capps

It will be sequential so we should see a bit of an improvement each quarter as we move through the year. It will probably be less of a step up in the first quarter because frankly we have to spend a little money to start getting all the savings so we are pre-spending a bit in Q1. So Q1 will be a slight improvement and then we would expect to see more improvement as we get to Q2, Q3, and Q4.

Unspecified Analyst - Deutsche Bank

And just any update on Mexico?

Vicki Capps

Mexico is doing great. We already are in process of moving a couple of production lines from some of the ReAble factories to Mexico and the transitions are going quite smoothly. We have quite a bit of capacity available down there to continue to move things. So I think we’re in very good shape as far as that’s concerned.

Unspecified Analyst - Deutsche Bank

Thanks very much.

Operator

Your next question comes from David Yu – Liberty Harbor

David Yu – Liberty Harbor

I have two questions. One is can you remind us on what the timeline you’d like to achieve the cost synergies? And where are you currently? And the second question is ’08 guidance the 30% margin, is that more revenue based or do you think there’s more a cost savings down the line.

Vicki Capps

The cost savings will…we will have initiated all of the actions to achieve that $50.6 million of cost savings during the course of this year, in fact much of the activities are already underway as we speak. We expect to have the full run rate of those savings achieved in 2009 and will be…its hard to gauge exactly how much of that will positively impact our actual results this year but it should approach at least half or so of the $50.6 million. We’re making good progress so as I said just a moment ago, we expect to see some of those savings positively impacting our P&L as early as here in the first quarter and I will be able to give you updates each quarter on exactly how much factors into our P&L.

David Yu – Liberty Harbor

Right an along the lines of the 30% EBITDA margin is that more top line based or is that further cost savings and I believe the $50 million was already included in the 27% currently?

Vicki Capps

It is and the 30% is the adjusted EBITDA margin so that would also include the full amount of the cost savings part of which will be will be realized this year and part of which will still be in anticipation of realizing next year. So that expansion mostly frankly comes from the cost savings because we don’t have much at all, really nothing in terms of the revenue synergies baked into our top line expectations. We know revenue synergies will come and hopefully that will permit us to over achieve at the top line which would be incremental contribution at the bottom line.

David Yu – Liberty Harbor

Right so it sounds like then to go from 27% to closer to 30% it’s more further cost savings rather than top line.

Vicki Capps

Well further cost savings as well as the normal contribution from the sales growth we expect which isn’t revenue synergies necessarily but we do expect to have something high single-digits, low double-digit top line growth for the total company for the year which contributes a higher profit margin. It’s more profitable revenue than the base line revenue obviously if it’s incremental.

David Yu – Liberty Harbor

Right perfect, thank you very much.

Operator

Your next question comes from the line of David Martin – BlueMountain Capital

David Martin – BlueMountain Capital

I’m sorry to ask you to repeat but I just wanted to…if you would just refresh me on…you’re talking about pro forma adjusted EBITDA and then you got to pro forma operating EBITDA, there were two dollar amounts that you subtracted out of there. Can you just refresh those for me?

Vicki Capps

Yes sure, so the adjusted EBITDA is $250.8 million includes $50.6 million of future cost savings related to the big DJO ReAble merger and about $16 million for the other acquisitions. So pro forma what we call operating EBITDA, was $184.1 million.

David Martin – BlueMountain Capital

Okay, that’s exactly what I needed because in the last comment you were talking about a $50.6 million number which is what I remembered. But crazily enough I had written down $56 million not $50.6 million. Alright, thanks.

Operator

Your next question comes from the line of Unspecified Analyst

Unspecified Analyst

I just had a question about the pro forma cash flows and is that kind of a benchmark you’re working with visa vie to gauge improvement? Could you just review what those pro forma cash flows are? Did you give us interest expense?

Vicki Capps

Interest expense is…depending on we do have a variable interest rate on part of our debt but for 2007 on a pro forma basis it would have been around $169 million. Capital expenditures I’d mentioned were about $21 million.

Unspecified Analyst

Right and no cash taxes or…?

Vicki Capps

Not much, a few million, you know $4 million to $5 million in cash taxes and then use of working capital of around $15 million on a pro forma basis.

Unspecified Analyst

For 2007?

Vicki Capps

Correct, for ’07.

Unspecified Analyst

Right and is that expected to be neutral in ’08 or can’t tell?

Vicki Capps

It would normally be a modest use of cash somewhere in the range of what I just said but we do have initiatives in place that are focused on improving working capital, particularly in the inventory area. So I think we have a chance for 2008 to do a little better and possibly even generate a little bit of cash from working capital.

Unspecified Analyst

Okay, great thank you very much.

Operator

Your next question comes from the line of Unspecified Analyst

Unspecified Analyst

Two questions, one is looking at the $185 million operating EBITDA does that include any expected synergies from the past six acquisitions that were done within the past two years, Iomed, Saunders, [inaudible]. I’m just wondering whether that has expected synergies from those acquisitions as opposed to the merger that we’re talking about here.

Vicki Capps

No it does not. That number doesn’t have any future cost savings in it.

Unspecified Analyst

Okay and then the second question would be considering the aggressive, maybe not necessarily aggressive but the acquisitive nature of the company in the past, what are your...what’s your strategy going forward on acquisitions, divestitures, et cetera? Could you just remind us of that?

Vicki Capps

Sure, I think for this year you’re going to see us highly focused on achieving the synergies we know are available through the merger we just did. Frankly the prize to be had is far too great to not spend our time and attention executing well on putting these businesses together. That’s not to say that acquisitions won’t potentially continue to play an important role in the future as we continue to build on the platform that we’ve created with this merger. But they’re definitely not a priority and frankly are pretty much off the table in the short term as we focus on the opportunity we have here. Divestitures, we don’t really have anything planned for now. We like all the businesses that are in the group and can see synergies between all of them and we will spend this year kind of confirming that that is the case and hopefully building on all of them.

Unspecified Analyst

Okay great, thank you.

Operator

Your next question comes from the line of [Ali Radinsky] – BridgeGate Capital Management

[Ali Radinsky] – BridgeGate Capital Management

I just wanted to confirm that I heard you correctly that your surgical implant quarter revenue was $17.5 million which was 33% growth over the year ago same quarter?

Vicki Capps

Correct.

[Ali Radinsky] – BridgeGate Capital Management

Okay what are you ascribing to such fast growth since for the year I believe you only showed 12.7% growth? Is it new products; is it…what’s going on there?

Vicki Capps

They’ve been doing a terrific job. It is some new products that have launched and particularly in the shoulder area. They’ve seen significant traction with several of the products they’ve launched over the last few years actually. And that is a segment where they are penetrating particularly well. There is also some international revenue in the surgical segment mix and with the change in exchange rates that’s given a bit of a tailwind as well.

[Ali Radinsky] – BridgeGate Capital Management

Okay, longer term given that you’re not spending a whole lot on this division relative to other players in this space, is this a division that you plan on keeping forever or is this something that you potentially you could look to divest since typically these things go for like 14x?

Vicki Capps

We actually think this business has a good place in this company and that there is potentially quite a bit of synergy between the surgical business and the former DJO business and I talked about it a little bit in my comments. On the DJO side of the merger, we’ve got significant relationships with orthopedic surgeons, in fact in our flagship knee bracing products, we have market share of over 40% which is a very high market share compared even to some of the big implant companies who are very happy to have say at 15% to 20% market share. So we have relationships with lots of orthopedic surgeons. And I think the opportunity to test those relationships to see if they can extend to the benefit of the surgical implant products, particularly when we can offer this package solution for the patients that include pain management, post-surgical bracing and other rehabilitation products is pretty interesting and something that we’re very focused on trying to make a success and definitely think its worth spending this year at least testing that thesis and seeing what we can do with the business and potentially even accelerate its growth further.

[Ali Radinsky] – BridgeGate Capital Management

I mean the other companies in the space they garner $2 to $300 million of revenue at least per quarter. You’re at $17.5 million. What do you need to do to really make a go in this space or do you just view yourself as a niche player?

Vicki Capps

I think we will be a niche player at least for the near term but we can’t compete and really don’t intend to compete with the big implant companies right in their sweet spots but some of our products address niches where they don’t really have big penetration yet and to the extent we can use our relationships to further penetrate opportunities that are smaller and potentially less interesting to the big guys but big and very interesting to us, I think we can make this a much bigger business than it is today.

[Ali Radinsky] – BridgeGate Capital Management

Thank you very much.

Operator

There are no further questions at this time; do you have any closing remarks?

Vicki Capps

Just to say thank you all very much for participating. We are looking forward to getting to know all of you on the debt side much better since we came from the DJO side where we were public on the equity side so good to meet the ones of you that we’ve met so far and looking forward to meeting more of you and thank you for listening and we look forward to updating you further in the very near future. Thanks very much.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: [e-mail]. Thank you!